statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome

Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in...

Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial

Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial Kyverna's KYV-101 Receives U.S. FDA IND...

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS) First-in-Disease Use of Kyverna...

KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation

KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation PR...

KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therapeutics, Inc. (Kyverna or the Company) (NASDAQ...

Why Kyverna Therapeutics Stock Is Sinking

Kyverna Therapeutics shares are falling Friday. The company released a presentation on KYV-101, its CD19 CAR T-cell candidate. Here's a look at the details:
read more...

Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology

Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology Kyverna Therapeutics and National Institutes of Health...

Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024

Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024 Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024 PR Newswire...

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results PR...

Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases

Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases...

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Volume	298,550.00
52-Wk High	$35.06
52-Wk Low	$6.75

KYTX Kyverna Therapeutics Inc.

About

Feed

News

Sentiment

Fundamentals